BNIP3 acts as transcriptional repressor of death receptor-5 expression and prevents TRAIL-induced cell death in gliomas

TR Burton1,2, ES Henson1,2, MB Azaq1,2, M Brown1,2, DD Eisenstat1,2,3,4 and SB Gibson*1,2

Glioblastoma multiforme (GBM) is the most common and malignant brain tumor, and current treatment modalities such as surgical resection, adjuvant radiotherapy and temozolomide (TMZ) chemotherapy are ineffective. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a novel cancer therapeutic agent for GBM because of its capability of inducing apoptosis in glioma cells. Unfortunately, the majority of glioma cells are resistant to TRAIL-induced apoptosis. The Bcl-2 nineteen kilodalton interacting protein (BNIP3) is a pro-cell death BH3-only member of the Bcl-2 family that is one of the highest expressed genes in hypoxic regions of GBM tumors. We previously found that BNIP3 is localized to the nucleus in GBM tumors and suppresses cell death in glioma cells. Herein, we have discovered when BNIP3 nuclear expression is knockdown in glioma cell lines and in normal mouse astrocytes, TRAIL and its death receptor, death receptor-5 (DR5) expression is increased. In addition, when nuclear BNIP3 expression is increased, the amount of TRAIL-induced apoptosis is reduced. Using a streptavidin pull-down assay, we found that BNIP3 binds to the DR5 promoter and nuclear BNIP3 binds to the DR5 promoter. Furthermore, nuclear BNIP3 expression in GBM tumors correlates with decreased DR5 expression. Taken together, we have discovered a novel transcriptional repression function for BNIP3 conferring a TRAIL resistance in glioma cells.

Cell Death and Disease (2013) 4, e587; doi:10.1038/cddis.2013.100; published online 11 April 2013

Subject Category: Cancer

Received 28.8.12; revised 28.1.13; accepted 06.2.13; Edited by G Raschella

1 Departments of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada; 2 Manitoba Institute of Cell Biology; University of Manitoba, Winnipeg, Manitoba, Canada; 3 Departments of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada and 4 Departments of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, Manitoba, Canada

*Corresponding author: SB Gibson, Manitoba Institute of Cell Biology, University of Manitoba, 675 McDermot Ave, Winnipeg, Manitoba R3E 0V9, Canada.

Keywords: BNIP3; TRAIL; gliomas; DR5; apoptosis

Abbreviations: AIF-1, apoptosis-inducing factor; BNIP3, Bcl-2 nineteen kilodalton interacting protein 3; BTTB, Brain Tumor Tissue Bank; DCIS, ductal carcinoma in situ; DMEM, Dulbecco’s modified essential medium; DR4, death receptor-4; DR5, death receptor-5; FFPE, formalin-fixed paraffin-embedded; GBM, glioblastoma multiforme; HDAC, histone deacetylase; HDI, histone deacetylase inhibitors; Δψm, mitochondrial membrane potential; miR145, microRNA 145; NS, non-specific promoter region; PCD, programmed cell death; PT, permeability transition; ROS, reactive oxygen species; TRAIL, Tumor necrosis-related apoptosis-inducing ligand; TMZ, temozolomide; Wt, wild type; YY1, Yin Yang 1
The Bcl-2 nineteen kilodalton interacting protein 3 (BNIP3) is a pro-cell death Bcl-2 family that is upregulated during hypoxia.\textsuperscript{20} When BNIP3 is upregulated, it induces caspase-independent cell death by localizing to the mitochondria and opening the permeability transition pore leading to loss of mitochondrial membrane potential (ΔΨm) and reactive oxygen species production.\textsuperscript{20,21} Recently, studies have implicated BNIP3 in the induction of autophagic cell death (programmed cell death type II) in malignant gliomas in response to hypoxia and arsenic trioxide treatment.\textsuperscript{22,23} BNIP3 is directly upregulated under hypoxic conditions by the transcription factor HIF-1, contributing to hypoxia-induced cell death.\textsuperscript{24–26} Paradoxically, BNIP3 is expressed at high levels in viable cells within hypoxic regions of tumors.\textsuperscript{27} This is partially due to nuclear localization of BNIP3 in tumors where BNIP3 fails to associate with the mitochondria, and promote cell death.\textsuperscript{28} This nuclear localization allows BNIP3 to associate with various promoters and repress their expression. We have found that BNIP3 binds to and represses the expression of apoptosis-inducing factor (AIF-1), contributing to resistance against TMZ-induced apoptosis.\textsuperscript{28}

Herein, we have discovered that BNIP3 localized to the nucleus represses DR5 expression and blocks TRAIL-induced apoptosis in glioma cells. In GBM tumors, nuclear BNIP3 expression correlates with lower levels of DR5 expression. This provides evidence for a novel mechanism for TRAIL resistance in glioma cells.

Results

Nuclear BNIP3 represses DR5 expression. We have previously identified that BNIP3 is expressed in the nucleus of primary human astrocytes and glioma cell lines, and it transcriptionally represses the expression of AIF.\textsuperscript{28} To further characterize genes transcriptionally repressed by BNIP3, we conducted Affymetrix oligonucleotide microarray analysis on total RNA from U251 and U251shRNABNIP3 cells on Affymetrix GeneChip Human U133 Plus 2.0 microarray chips. Raw GeneChip data were analyzed using the GeneSifter software (www.GeneSifter.net) to determine the fold change of gene expression between U251 parental and U251shRNABNIP3 cells (Supplementary Figure 1). We identified several genes upregulated in the TRAIL apoptotic pathway, including DR5. To confirm these results, we western blotted for protein in the TRAIL apoptotic pathway in U251 stably transfected cell lines, expressing different levels of BNIP3 (nuclear localization signal (NLS)-BNIP3 has higher levels of BNIP3 in the nucleus and short hairpin RNA (shRNA) BNIP3 has lower levels of total BNIP3). We found that DR5 expression significantly increased in cells lacking BNIP3 expression, whereas TRAIL, DR4, caspase 8, caspase 3, Bcl-xL and FLIP expression remained unchanged. BID expression was reduced in cell lacking BNIP3 (Figure 1a). As a control, we found the non-targeting BNIP3 failed to increased DR5 expression and decrease BNIP3 expression (Supplementary Figure 2). We also found similar result in increased DR5 expression in U87 cells overexpressing NLS-BNIP3 and knocked down for BNIP3 expression (Figure 1b). As a control, non-targeting siRNA also failed to reduce BNIP3 expression (Supplementary Figure 3). We further confirmed these results in mouse astrocytes isolated from knockout mice lacking BNIP3 expression. We found that in BNIP3 knockout cells lacked BNIP3 expression, whereas the heterozygote (BNIP3 \textsuperscript{+/-}) and wild-type (wt) mice brains expressed a significant amount of BNIP3 (Figure 1c). The expression levels of DR5 and TRAIL were increased, whereas there was little change in FAS receptor and caspase 8 in astrocytes lacking BNIP3 expression (KO) compared with wild type. Consistent with our previous study, AIF expression was increased in astrocytes lacking BNIP3 expression (Figure 1d). Finally, wild type or BNIP3 knockout mouse brain sections were fixed and immunostained with a DR5 antibody. In agreement with western blotting analysis, DR5 protein levels were increased in brain sections lacking BNIP3 expression (Figure 1e).

Nuclear BNIP3 represses the expression of DR5 mRNA expression. As DR5 protein was increased when BNIP3 expression was knocked down and it is a target for cancer therapy,\textsuperscript{10} we then sought to determine whether DR5 mRNA levels are regulated by nuclear BNIP3. We measured DR5 mRNA levels in the U251-transfected cell lines as described above. We found that the NLS-BNIP3-expressing cells had reduced DR5 mRNA expression compared with cells transfected with GFP (control cells). Concurrently, shRNA–BNIP3-expressing cells had significantly increased DR5 mRNA levels (Figure 2a) compared with parental controls. When wild-type BNIP3 was overexpressed in the cells, we observed a decrease in DR5 mRNA expression compared with control cells (Figure 2a). To confirm these results, we also used total RNA from mouse brains and determined the level of DR5 expression. We found that DR5 mRNA expression was increased compared with wild-type brains. This suggests that BNIP3 expression is regulating DR5 mRNA expression (Figure 2b).

Identification of a BNIP3 binding region in the promoter region of DR5. We have previously identified that BNIP3 can bind to DNA sequences identified from the ChIP DNA library.\textsuperscript{29} We found four regions within the DR5 promoter that could bind to nuclear BNIP3 (Supplementary Table 1). We chose the 18-bp sequence based on alignment of potential BNIP3 binding sites identified in the DR5 promoters, and these oligonucleotide probe was incubated with recombinant BNIP3 proteins. We observed a band with the wild-type BNIP3 protein corresponding with region 2 of the DR5 promoter (Figure 3a). To confirm these results, we used a tetracycline inducible system in HEK293 cells. The cells were lysed and incubated with oligonucleotide probes for the two regions on the DR5 promoter in the presence or absence of tetracycline. We found that BNIP3 bound to region 2 of the DR5 promoter after cells were induced by tetracycline (Figure 3b Supplementary Table 1). This indicates that nuclear BNIP3 binds to region 2 of the DR5 promoter.

To determine whether the nuclear BNIP3 is important for the regulation of DR5 gene transcription, a 60-bp fragment of the DR5 promoter was cloned into a luciferase reporter gene
 construct driven by a minimal CMV promoter to test whether this region can modulate expression of a reporter gene in vitro. This luciferase construct was transfected into U251 cell lines stably expressing vector alone, or shRNA against BNIP3 in a mammalian expression vector (lowers the levels of BNIP3 in the nucleus compared with parental). When BNIP3 expression was knocked down with shRNA, there was a significant increase in luciferase expression compared with controls (Figure 3c). As U251 cells express endogenous BNIP3, we used HEK293 cells, that fail to express BNIP3, to overexpress BNIP3 with a NLS (NLS-BNIP3) together with a luciferase plasmids that contain regions 1 or 2 of the DR5 promoter (pGL-R1 or pGL-R2) (Figure 3d). This showed that NLS-BNIP3 significantly repressed luciferase activity in the DR5 promoter containing region 2 (Figure 3e). These data strongly implicate this region of the DR5 promoter in repression of DR5 gene expression.

Nuclear BNIP3 expression blocks TRAIL-induced apoptosis. DR5 has an important role in TRAIL-induced apoptosis in glioma cells.10 To establish the functional consequences in glioma cells with altered DR5 levels due to nuclear BNIP3, we treated the U251 stable cell lines that have different nuclear BNIP3 levels with TRAIL (Figure 4).

Cells with high nuclear BNIP3 were more resistant to TRAIL-induced cell death (Figure 4a). Correspondingly, cells with low nuclear BNIP3 expression were more sensitive to TRAIL-induced cell death (Figure 4a). To confirm these results, we used a pulsefield gel electrophoresis to detect 50 kb DNA fragmentation in the U251 stable cell lines. We discovered that cells that have high nuclear BNIP3 and low DR5 expression contain less DNA fragmentation than parental controls when treated with TRAIL. In cells that have low nuclear BNIP3 and high DR5 expression, increased DNA fragmentation was detected compared with parental controls (Figure 4b). To confirm that nuclear BNIP3-regulated DR5 expression leads to cell death, caspase 3 activity was measured in the U251 stable cell lines and parental controls after TRAIL treatment. There was activation of caspase 3 activity following TRAIL treatment, but caspase 3 activity was lower in the U251-NLS-BNIP3 cell line (Figure 4c). We also transfected cells with NLS-BNIP3 and shRNA
against BNIP3. We found cleaved caspase 3 increased with TRAIL treatment and was further increased with the knockdown of BNIP3, whereas NLS-BNIP3 reduced cleaved caspase 3 (Supplementary Figure 3).

To determine whether mitochondrial release of proteins was affected by nuclear BNIP3 following TMZ or TRAIL treatment, TMZ and TRAIL-treated U251 cells were fractionated into nuclear and cytoplasmic lysates, and western blotted for AIF. We found that AIF protein expression in the nucleus increased after both TMZ and TRAIL treatment, indicating release from the mitochondria (Figure 4d). We also confirmed that NLS-BNIP3 was mainly expressed in the nuclear fraction (Supplementary Figure 5). An increase in AIF expression in the cytoplasm and in total cell extracts was also observed after both TMZ and TRAIL treatment (Figure 4d). Endonuclease G is also released from the mitochondria and localized in the nuclear following TRAIL treatment (Figure 4d). After treatment, BNIP3 levels in the nucleus decreased and increased in the cytoplasm (Figure 4d) similar to what happened under hypoxia. HDAC1 and caspase 8 antibodies were used as nuclear and cytoplasmic controls, respectively, to determine the amount of protein cross-contamination between nuclear and cytoplasmic lysates.

**Nuclear localized BNIP3 in primary human GBM tumors correlates with low DR5 expression.** Nuclear BNIP3 has been detected in GBMs, lung, and breast tumors. DR5 expression has been observed to be altered in GBM tumors, and high expression for DR5 is associated with better survival in GBM patients. As both nuclear localization of BNIP3 and DR5 expression showed variable patterns in GBM tumors, we asked whether nuclear BNIP3 correlated with levels of DR5 expression in GBM tumors. We immunostained formalin-fixed (FFPE) paraffin-embedded sections of primary GBM tumors with antibodies against BNIP3 and DR5. Tumors were counterstained for DNA with DAPI to identify the nucleus of the cells. To examine the localization of BNIP3 in GBM tumors, 14 tumors were graded according to whether BNIP3 was highly nuclear in localization, moderately nuclear or had low or no nuclear staining. The same tumors were graded for DR5 expression. Grading of the tumors was analyzed by a Chi-squared test and was statistically significant (P < 0.05), supporting that tumors with high nuclear BNIP3 levels have low DR5 expression, whereas tumors that have low nuclear BNIP3 have correspondingly high DR5 expression (Table 1). Two representative GBM tumors containing high and low nuclear BNIP3 expression, respectively, were immunostained for DR5, showing that nuclear BNIP3 correlated with lower DR5 expression (Figure 5a). Consistent with these findings, nuclear BNIP3 expression was associated with lower DR5 expression by immunoblotting of lysates obtained from unfixed frozen GBM samples matched to the FFPE tumor sections (Figure 5b). Thus, these data provides strong evidence consistent with nuclear BNIP3 repression of the expression of the DR5 gene in GBM tumors.

**Discussion**

We have discovered that normal astrocytes localize BNIP3 to the nucleus, preventing its pro-death function. This mechanism is exploited in GBM tumors, where upregulation of BNIP3 in the nucleus occurs in the majority of tumors (60%). Nuclear localization of BNIP3 is found in the lung, breast and cervical tumors, as well as in focal brain ischemia. In ductal carcinoma in situ of the breast, nuclear BNIP3 staining is present, but is significantly reduced in invasive breast tumors. In addition, nuclear BNIP3 was significantly correlated with a shorter disease-free survival. It was observed that nuclear localization of BNIP3 occurred in a subset of cases that had a particularly poor prognosis. These translational research studies provide strong evidence that nuclear localized BNIP3 in tumor cells is a phenotype selected to enhance the survival of tumor cells. We have now discovered that BNIP3 has a role in repressing DR5 expression and blocking TRAIL-induced apoptosis.

Cancer-specific molecules have been identified and used as potential targets for GBM therapy. A particularly promising
A novel therapeutic approach for GBM is the activation of the death receptor pathway through the treatment with the death receptor ligand TRAIL. TRAIL is an effector molecule involved in immune surveillance and is important for the elimination of virally infected and cancer cells. The ability of TRAIL to induce apoptosis in normal cells appears very limited, where it has been shown to induce apoptosis in glioma cells. Recombinant versions of TRAIL have advanced into clinical trials for a variety of solid tumors. GBM is an attractive target for TRAIL therapy owing to the expression of DR5 and to a lesser extent DR4. The expression levels of these receptors have also been correlated with longer survival times for GBM patients. Unfortunately, many glioma cells are resistant to TRAIL-induced apoptosis, putting into question the clinical usefulness of TRAIL as a treatment. Our discovery that nuclear BNIP3 represses DR5 expression in both glioma cells and normal astrocytes, suggests that TRAIL treatment could be effective if nuclear BNIP3 transcriptional repression was inhibited.

**Figure 3** BNIP3 binds to a specific region in the DR5 promoter. (a) Oligonucleotide probes containing four different putative BNIP3 DNA binding sequences (Supplementary Table 1) from the promoter region of DR5 (R1-4), beads alone (beads) and a non-specific promoter region were incubated with recombinant BNIP3 protein. Input indicates lysate alone without beads or DNA. Interestingly, only the oligonucleotide containing region 2 of DR5 showed binding with BNIP3. (b) This pull-down experiment was repeated using lysates from HEK293 cells that stably express BNIP3 under the control of a Tet-ON promoter. Without tetracycline, BNIP3 expression is not seen in the beads alone, R1, R2 or the non-specific control. However, in the presence of tetracycline, binding is again observed in region 2. (c) A 60-bp fragment of the DR5 promoter was cloned into the luciferase reporter gene construct and then transfected into U251 parental cells, and U251 stably expressing shRNA against BNIP3. All cells were co-transfected with a beta-galactosidase vector for control of transfection efficiency. Luciferase activity was measured by a Softmax Pro Luminometer. These results are representative of three independent experiments. (d) HEK293 cells were transfected with BNIP3-NLS expression vector or vector alone (pCDNA3) in combination with luciferase vector containing the DR5 promoter region 1 or 2. Cells were lysed and western blotted for BNIP3 and actin as a loading control. (e) Transfected HEK293 cells were also measured for luciferase activity as described above. These results are representative of the three independent experiments. * represented statistical significance from three independent experiments.

Novel mechanisms for Bcl-2 family members in the nucleus have been described. The BH3-only member of the Bcl-2 family BID is localized to the nucleus and has a role in the DNA damage response, and regulates the cell cycle. In addition, nuclear Bcl-2 inhibits transcription factor activation and alters the expression of DNA repair enzymes. We have previously identified that nuclear BNIP3 acts as a transcriptional repressor binding to the AIF promoter, thereby preventing apoptosis. Indeed, the region where BNIP3 binds contains a sequence that is homologous to a consensus repressor signal for neural-specific genes. We have found similar regions within the DR5 promoter and in cells knocked down for nuclear BNIP3, the promoter activity was increased. Besides AIF and DR5, BNIP3 may bind to multiple promoters and alter gene expression in many different types of cancer cells. Nevertheless, this unique BNIP3 repressor function for DR5 gene alters TRAIL-induced apoptosis in glioma cells.
and could be an important mechanism for TRAIL resistance in GBM tumors.

Besides transcription factors upregulating DR5 expression, transcriptional repressors have been implicated in regulating DR5 expression, but are less well characterized. The transcriptional repressor Yin Yang 1 binds to the DR5 promoter and blocks DR5 transcriptional activation. In addition, HDAC blocks gene transcription by deacetylating both histones and transcription factors. Under growth factor stimulation, HDAC1 is recruited to the DR5 gene, whereas under apoptotic stimuli HDAC1 is not recruited. This differential recruitment is mediated by NFκB, where under growth factor stimulation NFκB binds to HDAC1 and the DR5 gene, whereas NFκB fails to bind to HDAC1 under apoptotic conditions. BNIP3 also represses DR5 expression and we have previously shown that BNIP3 forms a complex with HDAC1. HDAC inhibitors such as VPA are effective at inducing cell death in glioma cells and increase AIF expression, suggesting inactivation of the BNIP3 repressor activity. Furthermore, DR5 expression is increased by HDAC inhibitors. These studies indicate that DR5 expression is dynamically regulated and BNIP3

---

Figure 4  TRAIL-induced apoptosis is blocked by nuclear BNIP3. (a) U251 parental, U251shRNABNIP3 and U251NLS-BNIP3 stable cells were treated with 1 ng/ml of TRAIL for 24 h or DMSO for control. Percentage cell death was determined by acridine orange staining. Error bars represent the S.E. determined from three independent experiments. * denotes a P-value <0.05 representing statistical significance between U251 parental and U251shRNABNIP3, as well as between U251shRNABNIP3 and U251NLS-BNIP3. (b) U251 parental, U251shRNABNIP3 and U251NLS-BNIP3 stable cells were treated with 1 ng/ml of TRAIL for 24 h or DMSO for control, and then genomic DNA was extracted and run on a BioRad pulse field gel apparatus. The arrow indicates ~ where the 50 kb DNA fragments migrate. This experiment was repeated three times and results were quantified by densitometry. (c) U251 parental and U251NLS-BNIP3 stable cells were treated with 1 ng/ml TRAIL for 24 h. Relative caspase 3 activity was measured as outlined in the Materials and Methods section. These results are representative of the three independent experiments. (d) Cytoplasmic and nuclear fractions were isolated from U251 cells that were untreated, or treated with TMZ and TRAIL as above. The lysates were western blotted for AIF, EndoG, BNIP3 (T7 antibody), HDAC1 (nuclear protein) and caspase 8 (cytoplasmic protein). Caspase 8 and HDAC1 were used for cytoplasmic and nuclear controls. The blots were stripped and reprobed with antibodies against actin for loading control.
Expected the presence of 5% CO₂ at 37 units/ml penicillin/streptomycin. The cell lines were grown in a humidified incubator in supplemented with 10% fetal bovine serum and 100
pyruvate, 0.3% glucose and 100 units/ml penicillin/streptomycin. Mouse astrocytes was cultured in Dulbecco’s modified essential medium (DMEM), respectively) were cultured in DMEM/F12 supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM MEM sodium
pyruvate, 0.3% glucose and 100 units/ml penicillin/streptomycin. Mouse astrocytes were passaged in DMEM/F12 supplemented with 10% fetal bovine serum and 100
units/ml penicillin/streptomycin. The cell lines were grown in a humidified incubator in the presence of 5% CO₂ at 37°C. In transfection experiments, the cells were plated
48 h before transfection to achieve ~60% confluence. The HEK293 cell line was transfected with Lipofectamine (Invitrogen; Life Sciences, Burlington, ON, Canada), the U87 cell line was transfected using Gene porter (GTS) and the U251 cell line using Effectene (Qiagen, Toronto, ON, Canada) as per the manufacturer’s instructions.

Materials and Methods

Cell culture and transfections. Human glioblastoma cell lines U251 (obtained from Dr. VW Yong, University of Calgary and Dr. C Hao, Emory University, respectively) were cultured in Dubcco’s modified medium (DMEM), supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM MEM sodium pyruvate, 0.3% glucose and 100 units/ml penicillin/streptomycin. Mouse astrocytes were passaged in DMEM/F12 supplemented with 10% fetal bovine serum and 100 units/ml penicillin/streptomycin. The cell lines were grown in a humidified incubator in the presence of 5% CO₂ at 37°C. In transfection experiments, the cells were plated
48 h before transfection to achieve ~60% confluence. The HEK293 cell line was transfected with Lipofectamine (Invitrogen; Life Sciences, Burlington, ON, Canada), the U87 cell line was transfected using Gene porter (GTS) and the U251 cell line using Effectene (Qiagen, Toronto, ON, Canada) as per the manufacturer’s instructions.

Cryopreservation of mouse brains. Mice were perfused with paraformaldehyde and the brains removed and fixed overnight in 4% paraformaldehyde

| BNIP3 localization | Expressed (0-1+) | Overexpressed (2+) | Strongly overexpressed (3+) | Total |
|--------------------|------------------|---------------------|-----------------------------|-------|
| Actual             |                  |                     |                             |       |
| Nuclear (3+)       | 3                |                     |                             | 7     |
| Moderate nuclear (2+) | 9                | 0                    |                             | 9     |
| Low nuclear (0-1+) | 6                | 2                    | 6                           | 14    |
| Expected            |                  |                     |                             |       |
| Nuclear (3+)       | 2.33             |                     |                             | 7     |
| Moderate nuclear (2+) | 3                | 3                    |                             | 9     |
| Low nuclear (0-1+) | 4.67             | 4.67                 | 4.67                        | 14    |
| Chi-squared        |                  |                     |                             | 0.00026 |

A total of 14 GBM tumors were scored for BNIP3 localization and then graded for DR5 expression levels. We predict that there would be an even distribution of DR5 expression across the different levels of BNIP3; however, tumors that had high levels of BNIP3 in the nucleus had lower levels of DR5, and when there were lower levels of BNIP3 in the nucleus there were higher levels of DR5. Chi square analysis showed that these differences were highly significant (P<0.001).

has a role in controlling DR5 expression in glioma cells and astrocytes. Overall, nuclear BNIP3 downregulates DR5 expression in glioma cells, leading to resistance to TRAIL-induced cell death. This may be relevant to GBM tumor cell survival because BNIP3 is primarily localized in the nucleus in the majority of GBM tumors and correlates with lower levels of DR5 expression. This provides a novel and potentially important mechanism for repressing DR5 expression and could be a future target for therapy rendering GBM tumor sensitivity to TRAIL therapy.

Table 1 DR5 expression levels in GBM tumors correlates with nuclear BNIP3 levels

| BNIP3 localization | Expressed (0-1+) | Overexpressed (2+) | Strongly overexpressed (3+) | Total |
|--------------------|------------------|---------------------|-----------------------------|-------|
| Actual             |                  |                     |                             |       |
| Nuclear (3+)       | 3                |                     |                             | 7     |
| Moderate nuclear (2+) | 9                | 0                    |                             | 9     |
| Low nuclear (0-1+) | 6                | 2                    | 6                           | 14    |
| Expected            |                  |                     |                             |       |
| Nuclear (3+)       | 2.33             |                     |                             | 7     |
| Moderate nuclear (2+) | 3                | 3                    |                             | 9     |
| Low nuclear (0-1+) | 4.67             | 4.67                 | 4.67                        | 14    |
| Chi-squared        |                  |                     |                             | 0.00026 |

A total of 14 GBM tumors were scored for BNIP3 localization and then graded for DR5 expression levels. We predict that there would be an even distribution of DR5 expression across the different levels of BNIP3; however, tumors that had high levels of BNIP3 in the nucleus had lower levels of DR5, and when there were lower levels of BNIP3 in the nucleus there were higher levels of DR5. Chi square analysis showed that these differences were highly significant (P<0.001).

Overall, nuclear BNIP3 downregulates DR5 expression in glioma cells, leading to resistance to TRAIL-induced cell death. This may be relevant to GBM tumor cell survival because BNIP3 is primarily localized in the nucleus in the majority of GBM tumors and correlates with lower levels of DR5 expression. This provides a novel and potentially important mechanism for repressing DR5 expression and could be a future target for therapy rendering GBM tumor sensitivity to TRAIL therapy.

Isolation of astrocytes. Newborn mice were killed by decapitation and then the brains were removed and placed in ice-cold serum-free media. The cortex was then dissected out and chopped into small pieces and then vortexed and filtered through 70 and 10 μm filters in sequence. Cells were then diluted in media with serum at a final concentration of 2-5 x 10⁶/ml. Cultures were kept at 37°C, 5% CO₂ changing the media after the first 3 days, and then twice a week after that. During media changes, the dishes were swirled to detach contaminating glial cells from the astrocytes. Cultures became confluent between 10 and 14 days and reached functional maturity 14 days after that. Cells were stained with GFAP to confirm the purity of culture.

Plasmids. A partial DR5 promoter sequence was inserted into the pGL3 promoter vector and pGL3 control vector, as well as a scrambled control using Nhe1 and Xho1 restriction enzymes.
The mutations in the NLS-BNIP3 plasmid were created by QuikChange site-directed mutagenesis (Stratagene, Agilent, Santa Clara, CA, USA), deleting 5 amino acids (IEIRR, 100–104) with primers:

Fwd: 5'-cctccctgcatATGGTGATGGTGATGATGcccgggcgctcc-3'
Rev: 5'-ggagcgcccgggCATCATCACCATCACCATatgcaggaggag-3'

The mutations in the NLS-BNIP3 plasmid were created by QuikChange site-directed mutagenesis (Stratagene, Agilent, Santa Clara, CA, USA), deleting 5 amino acids (IEIRR, 100–104) with primers:

Fwd: 5'-cctccctgcatATGGTGATGGTGATGATGcccgggcgctcc-3'
Rev: 5'-ggagcgcccgggCATCATCACCATCACCATatgcaggaggag-3'

The mutations in the NLS-BNIP3 plasmid were created by QuikChange site-directed mutagenesis (Stratagene, Agilent, Santa Clara, CA, USA), deleting 5 amino acids (IEIRR, 100–104) with primers:

Fwd: 5'-cctccctgcatATGGTGATGGTGATGATGcccgggcgctcc-3'
Rev: 5'-ggagcgcccgggCATCATCACCATCACCATatgcaggaggag-3'

The mutations in the NLS-BNIP3 plasmid were created by QuikChange site-directed mutagenesis (Stratagene, Agilent, Santa Clara, CA, USA), deleting 5 amino acids (IEIRR, 100–104) with primers:

Fwd: 5'-cctccctgcatATGGTGATGGTGATGATGcccgggcgctcc-3'
Rev: 5'-ggagcgcccgggCATCATCACCATCACCATatgcaggaggag-3'

The mutations in the NLS-BNIP3 plasmid were created by QuikChange site-directed mutagenesis (Stratagene, Agilent, Santa Clara, CA, USA), deleting 5 amino acids (IEIRR, 100–104) with primers:

Fwd: 5'-cctccctgcatATGGTGATGGTGATGATGcccgggcgctcc-3'
Rev: 5'-ggagcgcccgggCATCATCACCATCACCATatgcaggaggag-3'

The mutations in the NLS-BNIP3 plasmid were created by QuikChange site-directed mutagenesis (Stratagene, Agilent, Santa Clara, CA, USA), deleting 5 amino acids (IEIRR, 100–104) with primers:

Fwd: 5'-cctccctgcatATGGTGATGGTGATGATGcccgggcgctcc-3'
Rev: 5'-ggagcgcccgggCATCATCACCATCACCATatgcaggaggag-3'...
emission filter. were read on a SpectraMax GeminiXS using a 400 nm excitation and 505 nm to lyse for 10 min. Reaction buffer containing DTT and the DEVD-AFC substrate Briefly, samples were trypsinized and resuspended in cell lysis buffer and allowed Caspase 3 activity was measured using the Caspase 3 assay kit from Abcam (ab39383) as per manufactures instructions. Conflict of Interest

1. Gumey JG, Kadan-Lottick N. Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol; 2001; 13: 165–166.
2. Chamberlain CM. Treatment options for glioblastoma. Neurosurg Focus 2006; 20: E2.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol; 2007; 114: 97–109.
4. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Cell 2004; 9: 777–783.
5. Henson ES, Johnston JB, Gibson SB. The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk Lymphoma 2008; 49: 27–35.
6. Wu GS, Kim K, el-Deyry WS. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53 tumor suppressor to caspase activation and apoptotic death. Adv Exp Med Biol 2000; 465: 143–151.
7. Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000; 20: 205–212.
8. Mendonza FJ, Ishido G, Hu X, Gibson SB. Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide toxicity. Apoptosis. 2003; 8: 756–770.
9. Kullmen J, Mooj JJ, Platteel I, Hoving EW, van der Graaf W, Span MM et al. TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. J Neurooncol 2006; 78: 161–171.
10. Kullmen JJ, Bremer E, Mooj JJ, den Dunnen WF, Helrich W. Review on: TRAIL for malignant glioma therapy? Neuropathol Appl Neurobiol 2010; 36: 168–182.
11. Panner A, Crane CA, Weng C, Feletti A, Parsa AT, Pieper RO. A novel PTN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res 2009; 69: 7911–7916.
12. Nagane M, Pan G, Weddle JJ, Dxt VM, Cavenne WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000; 60: 847–853.
13. Ohtsuka T, Buchsbaum D, Oliver P, Majiak S, Kimberly R, Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK3p38 and mitochondrial death pathway. Oncogene 2003; 22: 2034–2044.
14. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments death receptor-induced apoptosis in breast cancer. Cancer Res 1999; 59: 734–741.
15. Wactawski H, Miller RE, Aniel K, Glinka B, Griffith TS, Kumbh M et al. Tumoral activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157–163.
16. Kabore AF, Sun J, Hu X, McKee K, Johnston JB, Gibson SB. The TRAIL apoptotic pathway mediates prosapotesin induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 2006; 11: 1175–1193.
17. Kim K, Fisher MJ, Xu SQ, el-Deyry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6: 335–346.
18. Takimoto R, el-Deyry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intrinsic sequence-specific DNA-binding site. Oncogene 2000; 19: 1735–1743.
19. Shetty S, Gladden JB, Henson ES, Hu X, Villanueva J, Haney N et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines. Apoptosis 2002; 7: 413–420.
20. Vande Velde C, Cizeau J, Dubik D, Altjomt J, Brown T, Israels S et al. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol Cell Biol 2003; 20: 5454–5468.
21. Kim JY, Cho JJ, Ha J, Park JH. The carboxy terminal C-tail of BNip3 is crucial in induction of mitochondrial permeability transition in isolated mitochondria. Arch Biochem Biophys 2002; 398: 147–152.
22. Kanzawa T, Zhang L, Xiao L, Germano IM, Kondo Y, Kondo S. Areaicin trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene 2005; 24: 980–991.
23. Azad MB, Chen Y, Henson ES, Cizeau J, McMillian-Ward E, Israels SJ et al. Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3. Autophagy 2008; 4: 195–204.
24. Kothari S, Cizeau J, McMillian-Ward E, Israels SJ, Bailes E, Enns K et al. BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 2003; 22: 4734–4744.
25. Bruck RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 2000; 97: 9062–9067.
26. Bacon AL, Harris AL. Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Am Med 2004; 36: 530–539.
27. Sowter HM, Radcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1-dependent regulation of BNIP3 induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 2001; 61: 6669–6673.
28. Burton TR, Henson ES, Baijal P, Eisenstadt DD, Gibson SB. The pro-cell death Bcl-2 family member, BNIP3, is localized to the nucleus of human glial cells: Implications for glioblastoma multiforme tumor cell survival under hypoxia. Int J Cancer 2006; 118; 710–713.
29. Burton TR, Eisenstadt DD, Gibson SB. BNIP3 (Bcl-2 19 Ida interacting protein) acts as transcriptional repressor of apoptosis-inducing factor expression preventing cell death in human malignant gliomas. J Neurosci 2009; 25: 4199–4199.
30. Giannornolodi A, Koukourakis MI, Sowter HM, Shivrid E, Gibson S, Gatter KC et al. BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer. Clin Cancer Res 2004; 10: 5566–5571.
31. Tan EY, Camo L, Han C, Turley H, Pessellia F, Gatter KC et al. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Clin Cancer Res 2007; 13(2) (Pt 1): 467–474.
32. Sowter HM, Farguson M, Pym C, Watson P, Baijal P, Han C et al. Expression of the cell death genes BNIP3 and NIX in ductal carcinoma in situ of the breast; correlation of BNIP3 levels with necrosis and grade. J Pathol 2003; 201: 573–580.
33. Dettitore C, Yuste VJ, Moubarak RS, Bras M, Robert N, Susin SA. Identification and characterization of Atf6a2, a mitochondrial apoptosis-inducing factor (AIF) isoform with NADH dehydrogenase activity. J Bio Chem 1999; 274: 18957–18968.
34. Lee JW, Jeon EG, Song YH, Kim SY, Nam SW, Kim SH et al. Immunohistochemical analysis of apoptosis-inducing factor (AIF) expression in gastric carcinomas. Pathol Res Pract 2006; 202: 497–501.
35. Leo C, Hong LM, Hocke M. Hypoxia and expression of the proapoptotic regulator BNIP3 in cervical cancer. Int J Gynecol Cancer 2006; 16: 1314–1320.
36. Schmidt-Kastner R, Aguirre-Chen C, Kietsmann T, Saul I, Busto R, Ginsberg MD. Nuclear localization of the hypoxia-regulated pro-apoptotic protein BNIP3 after global brain ischemia in the rat hippocampus. Brain Res 2004; 1001: 133–142.
37. Zinkel SS, Hurko AE, Gross A. Bcl-2 and Bax play a role in the DNA damage response. Cell 2007; 130: 9–10; author reply 10–11.
38. Wang Q, Gao F, May WS, Zhang Y, Flagg T, Deng X. Bcl-2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathway. Mol Cell 2008; 29: 488–498.
39. Massaad CA, Porter BP, Tagliatalata G. Inhibition of transcription factor activity by nuclear compartment-associated Bcl-2. J Biol Chem 2004; 279: 54470–54478.
40. Karadush MF, DeBriere E. Neuronal restrictive silencing element is found in the KCCI gene: molecular basis for KCC2-specific expression in neurons. J Neurophysiol 2001; 85: 995–997.
41. Chen X, Gong J, Zeng H, Chen N, Huang R, Huang Y et al. MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. Cancer Res 2010; 70: 2728–2738.

42. Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 2007; 6: 1387–1399.

43. Shabason JE, Tofflon PJ, Camphausen K. Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med 2011; 15: 2735–2744.

44. Shetty S, Graham BA, Brown JO, Hu X, Vegh-Yarema N, Harding G et al. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 2005; 25: 5404–5416.

45. Booy EP, Henson ES, Gibson SB. Epidermal growth factor regulates Md-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer. Oncogene 2011; 30: 2367–2378.

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)